RecruitingNCT06885853
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
90 participants
Start Date
May 7, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Men aged over 18 years
- Have received two doses of MVA-BN vaccine as an initial schedule
- Eligible for a booster dose of MVA-BN (according to the HAS recommendation)
- Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment
- Covered by social security (excluding AME)
Exclusion Criteria4
- History of mpox (virologically confirmed)
- Be under guardianship or curatorship
- Be subject to a judicial protection measure
- Have a contraindication to vaccination against mpox
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06885853